Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our modelAll three major indices are trading down today with the Dow Jones Industrial Average (^DJI) trading down 20 points (-0.2%) at 12,795 as of Monday, Nov. 12, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,283 issues advancing vs. 1,555 declining with 129 unchanged.The Health Care sector currently is unchanged today versus the S&P 500, which is down 0.1%. A company within the sector that increased today was Baxter International (BAX), up 1.0%. A company within the sector that fell today was Express Scripts (ESRX), up 0.8%.TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:5. Regeneron Pharmaceuticals (REGN) is one of the companies pushing the Health Care sector higher today. As of noon trading, Regeneron Pharmaceuticals is up $3.22 (2.3%) to $143.96 on light volume Thus far, 180,127 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 712,100 shares. The stock has ranged in price between $142.24-$144.89 after having opened the day at $142.63 as compared to the previous trading day's close of $140.74. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $13.0 billion and is part of the drugs industry. The company has a P/E ratio of 69.9, above the S&P 500 P/E ratio of 17.7. Shares are up 148.3% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.
Latest Headlines about AMGN
Latest from TheStreet Wire
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV